92 related articles for article (PubMed ID: 2204002)
1. Possibilities and limitations of immunological marker analyses for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Ludwig WD; van Dongen JJ; Thiel E; Teichmann JV; Hofmann J; Riehm H
Onkologie; 1990 Jun; 13(3):166-74. PubMed ID: 2204002
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.
van Dongen JJ; Breit TM; Adriaansen HJ; Beishuizen A; Hooijkaas H
Leukemia; 1992; 6 Suppl 1():47-59. PubMed ID: 1548936
[TBL] [Abstract][Full Text] [Related]
4. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.
van Wering ER; Beishuizen A; Roeffen ET; van der Linden-Schrever BE; Verhoeven MA; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1995 Sep; 9(9):1523-33. PubMed ID: 7658722
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic and enzymatic markers of acute infantile lymphoblastic leukemias].
González M; Tamagnini G; San Miguel JF; Lopes DT; Mateos G; Caballero MD; Ribeiro L; López Borrasca A
An Esp Pediatr; 1984 Sep; 21(3):222-8. PubMed ID: 6594963
[TBL] [Abstract][Full Text] [Related]
7. Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies.
Zipf TF; Fox RI; Dilley J; Levy R
Cancer Res; 1981 Nov; 41(11 Pt 2):4786-9. PubMed ID: 6975160
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Bodner SM; Casavant CH; McHugh TM; Stites DP
Diagn Immunol; 1985; 3(3):139-44. PubMed ID: 2932276
[TBL] [Abstract][Full Text] [Related]
10. Relevance of 3A1 monoclonal antibody in the diagnosis of T-cell acute lymphoblastic leukemia.
Lopez M; De Rossi G; Bonomo G; Napolitano M; Pasqualetti D; Guglielmi C; Annino L; Pandolfi F
Diagn Immunol; 1985; 3(1):11-4. PubMed ID: 3873317
[TBL] [Abstract][Full Text] [Related]
11. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
Pawińska-Wasikowska K; Balwierz W
Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
[TBL] [Abstract][Full Text] [Related]
12. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
13. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
14. Shifts in expression of immunological cell markers in relapsed acute leukemia.
Tomová A; Babusíková O
Neoplasma; 2001; 48(3):164-8. PubMed ID: 11583283
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of minimal residual disease in high risk childhood acute lymphoblastic leukemia using an immunological approach during complete remission. AIEOP Cooperative Group for Immunology of Acute Leukemias.
Consolini R; Scamardella F; Legitimo A; Putti C; Granchi D; Paolucci P; Lippi A; Guazzelli C; Acquaviva A; Rosanda C
Haematologica; 1993; 78(5):297-305. PubMed ID: 8314159
[TBL] [Abstract][Full Text] [Related]
16. [Distribution of leukemia-associated antigens (CALLA, P24 antigen and P20 antigen) on childhood acute lymphoblastic leukemia cells and nonhematopoietic tissues].
Ochiai J; Komada Y; Shimizu K; Kamiya H; Sakurai M
Rinsho Ketsueki; 1987 Sep; 28(9):1522-7. PubMed ID: 2963922
[No Abstract] [Full Text] [Related]
17. Structure/function studies of the common acute lymphoblastic leukemia antigen (CALLA/CD10) expressed on human neutrophils.
McCormack RT; Nelson RD; LeBien TW
J Immunol; 1986 Aug; 137(3):1075-82. PubMed ID: 2941484
[TBL] [Abstract][Full Text] [Related]
18. A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Nadler LM; Ritz J; Hardy R; Pesando JM; Schlossman SF; Stashenko P
J Clin Invest; 1981 Jan; 67(1):134-40. PubMed ID: 6969730
[TBL] [Abstract][Full Text] [Related]
19. Antigen Expression on Blast Cells and Hematological Parameters at Presentation in Acute Lymphoblastic Leukemia Patients.
Naeem S; Bukhari MH
J Coll Physicians Surg Pak; 2015 Jun; 25(6):407-11. PubMed ID: 26100991
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
